Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. - Wikidata - wikimedia - TriplyDB

Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.

Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.

http://www.wikidata.org/entity/Q37360439

about

Immunotherapy of systemic sclerosis Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice Metabolic abnormalities in the pathogenesis of type 1 diabetes.Efforts to prevent and halt autoimmune beta cell destruction.Use of nonobese diabetic mice to understand human type 1 diabetes A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man.The pancreas in human type 1 diabetes.Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice.PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice.Stimulating IL-13 receptors on T cells: a new pathway for tolerance induction in diabetes?Immune therapy for treating type 1 diabetes: challenging existing paradigms.Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes Development of standardized insulin treatment protocols for spontaneous rodent models of type 1 diabetes.Strategies to target long-lived plasma cells for treating hemophilia A inhibitors.The granulocyte colony stimulating factor pathway regulates autoantibody production in a murine induced model of systemic lupus erythematosus.Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease.Type 1 diabetes: etiology, immunology, and therapeutic strategies.Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.Autologous regulatory T cells for the treatment of type 1 diabetes.Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Combinatorial drug delivery approaches for immunomodulation.Suppression of islet homeostasis protein thwarts diabetes mellitus progression.Adoptive T Regulatory Cell Therapy for Tolerance Induction.Deletion of the Men1 gene prevents streptozotocin-induced hyperglycemia in mice.Simultaneous Recognition of Allogeneic MHC and Cognate Autoantigen by Autoreactive T Cells in Transplant Rejection.Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 Diabetes Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes

P2860

Q24634395-4EA7B275-A60C-4C2E-B105-B056098B09E5 Q26850621-980000DE-2F09-44D4-BB5E-2D2857F7E351 Q28483660-5E2B0C65-DD3F-4467-9115-5689320A8033 Q28551036-F0F1888C-D63C-42CD-ABE4-336843F2CF61 Q33940335-036CF4D4-91F7-4F12-8C2D-51495AE11819 Q34077363-83248A35-1D17-4D1D-90F5-D3C9BB1BD7AA Q34078163-BC2560BB-97CA-4DA3-BCBD-714DF7434D76 Q34082857-6A5FC655-C7F2-486F-BE50-10FEC4BAAB22 Q34318993-373C94B3-A07C-4F9A-9137-E06C2FC9FB4C Q34448607-BAC33DC8-3F24-4BC4-B8DE-87A01C43E69B Q34496850-FBEBE20D-3931-4587-AF90-EF4A621F86BF Q34511576-C4A46A1D-21F5-41AC-9A9A-15023EF40488 Q35004384-0A3B3112-7C84-44F9-898C-3E1C9EEC35E9 Q35043465-8B36CB35-0E4C-4C9C-8596-F49C3F19FC58 Q35242386-5E90E34E-FBF6-49DC-BA0A-51784F00CDBA Q35242428-4C4DDD44-9F45-421E-AE94-EC1AA89D8E8E Q35405281-CC2D6E9F-811A-417F-A1FF-EF5778D17FE8 Q35563587-3C90338E-930F-4C5F-8ACF-3B3E67C155D0 Q36186226-B42E5374-7E7C-4BA9-B73C-7F2DFC11B430 Q36186271-38BB352B-A9B4-4F9C-A732-FDE55C0AC806 Q36321376-5D46FEA3-19FA-49D5-A443-CE8EF9EA1D91 Q36832899-D4B49E88-174C-4F2F-AB8C-A4375BAB3531 Q36903222-A08F0CC3-0B8D-46E1-9301-CB8372108B26 Q37088185-DB4D9814-A3F3-40A2-96B2-87E5020D7A89 Q37088225-4D75079F-8491-4D8C-B2E9-305CE8E46393 Q37367372-745F9287-7206-4737-AC05-9FC868C4FA0C Q37737987-86D1CBBD-81AB-4E38-B26E-0E4886446836 Q37830198-9058412B-B902-490E-B280-C5C042E572A5 Q37883029-F345E0C7-4F7D-4D82-8D06-729F4F3399A6 Q38030480-E278FA34-754F-4EB8-A9E6-80EC7800F520 Q38384138-24266B41-5D09-4E4B-8A46-31A0A61FFED2 Q38385236-56B3E42A-45E6-431B-97F2-69456D939834 Q38680602-3DA515EF-7BD5-400A-B06E-40A1534B6BFF Q38715653-41BE45BA-2894-4611-BFF6-3F4F2F496FEB Q40132561-AA85CACB-A823-469D-8FFC-24D2351F3308 Q42086741-296D6F61-0C30-425A-B7C2-54F16887568B Q48293644-CBA64B20-97FA-4867-BF1A-DCE7C274FF95 Q50702410-9E038805-6E22-4F22-9EA0-4F1B10BA8BB8 Q57163295-28A406CB-5F0B-412F-BCCD-7A2BDB5CB10E Q58773667-8B6C3283-CFB6-4E9E-9E10-6874A9DE5A7B

P2860

Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.

http://www.wikidata.org/entity/Q37360439

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immune depletion with cellular ...... tes in nonobese diabetic mice.

@en

Immune depletion with cellular ...... tes in nonobese diabetic mice.

@nl

type

label

Immune depletion with cellular ...... tes in nonobese diabetic mice.

@en

Immune depletion with cellular ...... tes in nonobese diabetic mice.

@nl

prefLabel

Immune depletion with cellular ...... tes in nonobese diabetic mice.

@en

Immune depletion with cellular ...... tes in nonobese diabetic mice.

@nl

P1433

Q37360439-258BEE06-C3D8-41B5-B78F-5C34325C81F9

P1476

Q37360439-FEF6FD1C-DB77-4348-AB8D-81961F113C91

P2093

Q37360439-106D0653-8E50-4B4E-B108-1F5A7D7D8738

Q37360439-1F780BD6-22B6-4DFB-B9B9-AC6E6C078EF6

Q37360439-4E3A123B-0A9A-4A9F-9BA1-B5120B698218

Q37360439-56421A52-1FFE-4253-ABCE-84834250D500

Q37360439-9D6E18C9-988E-4223-BC5E-8C4D7F4535E4

Q37360439-BA4E752D-761E-4EA2-8B3A-9044FAD52E77

Q37360439-C1261439-C1C8-4BC5-927C-22445DF295EE

Q37360439-CBA56714-C49F-4C9E-B04A-178ABD1703DC

Q37360439-EF88184C-CE69-4501-B2A8-B6F0F33DEC04

Q37360439-F9CCFD68-BD7A-4A68-9279-80F53A559BBB

P2860

Q37360439-04DBCB29-2D4B-45E8-80F8-5371A33D2241

Q37360439-0B8C1CC2-13FB-478B-B4A9-A95DBB4CA13F

Q37360439-147171C0-9C83-436D-83C5-78EEA758A9BE

Q37360439-1FB12415-027A-4A1F-A2A1-0A8A40018853

Q37360439-2129EF17-FC88-45D5-8131-2BF17D98FB5F

Q37360439-22678A65-332F-463E-A890-8FA3F28F0D09

Q37360439-2E5775D7-14E5-491E-8E53-76C086D95D49

Q37360439-3803204B-8469-41DE-A8D6-185098073A14

Q37360439-395F8879-8689-4562-B572-00E6EE3C7415

Q37360439-47E1E12A-9CAD-4529-B0D7-F49DA5D2F6A3

P304

Q37360439-FDE78C41-8D47-4795-BC75-615A3FE62126

P31

Q37360439-4B07D0F4-7CEA-4151-8E82-662670C5E0C2

P356

Q37360439-30E18A84-5427-48F1-9E82-C44B0808A9D2

P407

Q37360439-81520F19-3217-43AE-9D3B-82B94A9DF920

P433

Q37360439-8EFF18F9-70EB-49F6-A57A-6E9597EE15E3

P478

Q37360439-A34C8EF9-1677-46A2-99B7-4BD325523C4B

P50

Q37360439-22769A36-257C-4DFA-A435-949A8E4CD337

Q37360439-CCDCBEF0-F4CE-4552-B614-0BF2951713B3

Q37360439-E0EC8BE4-6EFB-4F3C-8268-78DE2B500E43

Q37360439-F95DF7AA-13DE-46FC-82BA-009DCD917682

P577

Q37360439-AB1CCE6C-BFCD-4523-B02A-0CFB88F3C2E6

P5875

Q37360439-D8A40DAC-8D21-4518-8C40-D4D42761ACF3

P698

Q37360439-70F51308-6114-4070-9ABC-11D5683B5F56

P932

Q37360439-3EB0AF57-92BC-4ADD-831A-4B9AA1E9C10B

P356

P1433

P1476

Immune depletion with cellular ...... tes in nonobese diabetic mice.

@en

P2093

Clayton E Mathews

http://www.w3.org/2001/XMLSchema#string

Desmond A Schatz

http://www.w3.org/2001/XMLSchema#string

John J Alexander

http://www.w3.org/2001/XMLSchema#string

John Williams

http://www.w3.org/2001/XMLSchema#string

Mark A Atkinson

http://www.w3.org/2001/XMLSchema#string

Matthew J Parker

http://www.w3.org/2001/XMLSchema#string

Michael J Haller

http://www.w3.org/2001/XMLSchema#string

Misty Troutt

http://www.w3.org/2001/XMLSchema#string

Scott Eisenbeis

http://www.w3.org/2001/XMLSchema#string

Sihong Song

http://www.w3.org/2001/XMLSchema#string

P2860

Opinion: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes

Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.

Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.

Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells.

Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.

Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice

Relationship between beta-cell mass and diabetes onset.

Immunotherapy for the prevention and treatment of type 1 diabetes.

Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment.

P304

2277-2284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB09-0557

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Martha Campbell-Thompson

Clive Wasserfall

Manuela Battaglia

P577

2009-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26692066

http://www.w3.org/2001/XMLSchema#string

P698

19628781

http://www.w3.org/2001/XMLSchema#string

P932

2750219

http://www.w3.org/2001/XMLSchema#string